Literature DB >> 1874603

A phase II clinical trial of diaziquone (AZQ) in the treatment of patients with recurrent leiomyosarcoma of the uterus. A Gynecologic Oncology Group study.

R E Slayton1, J A Blessing, K Look, B Anderson.   

Abstract

Based upon the activity observed in this trial, there does not appear to be a significant role for AZQ as a salvage agent for leiomyosarcoma of the uterus at the dose and schedule tested.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1874603     DOI： 10.1007/bf00175091

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  4 in total

1.  A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: an NRG Oncology/Gynecologic Oncology Group Study.

Authors:  Linda R Duska; John A Blessing; Jacob Rotmensch; Robert S Mannel; Parviz Hanjani; Peter G Rose; Don S Dizon
Journal:  Gynecol Oncol       Date:  2014-08-01       Impact factor: 5.482

2.  Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial.

Authors:  Martee L Hensley; John A Blessing; Robert Mannel; Peter G Rose
Journal:  Gynecol Oncol       Date:  2008-06       Impact factor: 5.482

3.  Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.

Authors:  Martee L Hensley; Michael W Sill; Dennis R Scribner; Jubilee Brown; Robert L Debernardo; Ellen M Hartenbach; Carolyn K McCourt; James R Bosscher; Paola A Gehrig
Journal:  Gynecol Oncol       Date:  2009-10-06       Impact factor: 5.482

4.  Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.

Authors:  Martee L Hensley; John A Blessing; Koen Degeest; Ovadia Abulafia; Peter G Rose; Howard D Homesley
Journal:  Gynecol Oncol       Date:  2008-04-18       Impact factor: 5.482
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.